(Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by Health Canada, in-warranty t:slim X2™ insulin pump users can now access full compatibility with ...

Insulin pump therapy, also known as continuous subcutaneous insulin infusion (CSII), is an important and evolving form of insulin delivery, which is mainly used for people with type 1 diabetes.

MARKHAM, Ontario — Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by Health Canada, in-warranty t:slim X2™ insulin pump ...

we have decided to discontinue our insulin patch pump program and initiate an organizational restructuring plan. We believe this approach will streamline operations, reduce costs and enhance our ...

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now discontinuing its patch pump program as part of a broader restructuring ...

Embecta said Tuesday that it will cancel its insulin patch pump program just months after receiving clearance from the Food and Drug Administration for its first product. The Parsippany, New ...

Embecta (Nasdaq:EMBC) announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan. Shares of EMBC ticked up 4.3% to $14.41 apiece before hours after ...

The Becton, Dickinson and Company (NYSE:BDX) spin-off announced that it decided to discontinue its insulin patch pump program and plans to initiate a restructuring plan. In July, Embecta ...

Added Jul 01, 2016 at 09:19AM EDT by QuazzleTheQaz.